BioAge doses first participant in Phase 2 QUELL-CV trial of NLRP3 inhibitor BGE-102

BioAge Labs, Inc.

BioAge Labs, Inc.

BIOA

0.00
  • BioAge Labs dosed the first participant in QUELL-CV, a Phase 2 trial of oral NLRP3 inhibitor BGE-102 for cardiovascular risk reduction.
  • Study will test three once-daily doses versus placebo in 160 adults with obesity and elevated inflammation.
  • Readout will assess whether BGE-102 lowers systemic inflammation, guiding dose selection for a planned Phase 3 program.
  • Phase 1 results were previously reported, showing the drug reduced inflammation and was well tolerated.
  • Topline Phase 2 data are expected in the second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.